• Like
Paolo Fanti, M.D.
Upcoming SlideShare
Loading in...5
×

Paolo Fanti, M.D.

  • 561 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
561
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. CURRICULUM VITAE Paolo Fanti, M.D. I. GENERAL INFORMATION Office Address Renal Section (111J-CDD), VA Medical Center, (mailing) Lexington, KY 40511 Telephone 859-233-4511 x 4449, or 859-281-4959 Fax 859-381-5976 E-mail pfanti0@pop.uky.edu Name of Specialty Board Internal Medicine Certificate or Specialty Board Licensure: Board of Nephrology of Italy Certified 1984 American Board of Internal Medicine Eligible 1991 ABIM, Nephrology Eligible 1992 Medical License: Kentucky #23571 1984 Italy 1979 II. EDUCATION Medical 1979 Medical Doctor, University of Bologna, College of Medicine, Magna Cum Laude Bologna, Italy Post-Graduate 1991-1992 Clinical Fellow in Nephrology University of Kentucky Medical Center (full-time) Lexington, KY 1984-1991 Resident in Internal Medicine and University of Kentucky Medical Center Research Fellow in Nephrology, Department of Internal Medicine (combined programs, full time) Lexington, KY 1983-1984 Resident in Internal Medicine University of Kentucky Medical Center (full-time) Lexington, KY 1981-1983 Research Fellow in Nephrology University of Kentucky Medical Center (full-time) Lexington, KY 1980-1981 Research Fellow in Nephrology University of Southern California, School of Medicine, (full-time) Los Angele s, CA 1980 Visiting Investigator University of California at Riverside 1979-1980 Clinical Fellow in Nephrology University of Bologna Medical Center (full-time) Bologna, Italy III. PROFESSIONAL & CLINICAL EXPERIENCE 1992-present Attending Physician and Nephrology University of Kentucky Medical Center Consultant Lexington, KY 1992-present Attending Physician and Nephrology VA Medical Center Consultant Lexington, KY IV. ACADEMIC APPOINTMENTS 2000-present Associate Professor of Medicine University of Kentucky Medical Center, Division of Nephrology, (full-time, with tenure) Bone & Mineral Metabolism, Lexington, KY 1993-present Associate Member of the Graduate University of Kentucky Graduate School, Department of Faculty Physiology and Biophysics, Lexington, KY 1992-present Staff Physician VA Medical Center (full-time) Lexington, KY
  • 2. Paolo Fanti, M.D. 1992-2000 Assistant Professor of Medicine University of Kentucky Medical Center, Division of Nephrology, (full-time) Bone & Mineral Metabolism, Lexington, KY V. ADVISING ACTIVITY Doctoral and Postdoctoral Trainees Supervised: 1999-2001 Tammy Hanna, Ph.D. candidate Soy protein use in early diabetic nephropathy. Human studies. in Nutritional Science 1993-1996 Jay Grider, Med. Student, Ph.D. Dissertation committee member. candidate in Physiology 1993-1995 Scott D. Carter, PhD candidate Recombinant growth hormone on bone quality in animal models. in Agriculture, Animal Science. 1988-1990 Jurgen Klein, M.D., Research Fellow Effect of aluminum on protein kinase activity of osteoblastic cells in culture. 1987-1990 Chingua Yao, Ph.D., Research Isolation of canine bone osteocalcin. Quantitation of osteocalcin in Fellow dog blood. 1987-1988 Robert W. Letton, Med. Student, Metabolism of vitamin D in osteoblastic cells in culture. Research Fellow VI. ADMINISTRATIVE ACTIVITY AND UNIVERSITY SERVICE 2000-present Ad Hoc Reviewer for the UKMC General Clinical Research Center 1994-present Director of the Renal Outpatient Clinic at the University of Kentucky Outpatient Clinic 1996-2000 Director of Subspecialty Clinics of the Department of Internal Medicine Outpatient Clinic. 1995-1998 Medical Director of the Interdisciplinary Renal Stone Clinic at the University of Kentucky Outpatient Clinic 1992-1998 Member of the Internship Selection Committee of the Department of Medicine 1987-1994 Coordinator of the Clinical Journal Club and Research Conference of the Division of Nephrology, Bone and Mineral Metabolism, weekly conference VII.SPECIAL ASSIGNMENTS 1998-present Editorial Board, Clinical Nephrology VIII.HONORS AND AWARDS 1992-1996 Physician-Scientist Award at the University of Kentucky Medical Center 1991 Resident Teaching Award for the academic year 1990-1991, from the Department of Medicine, University of Kentucky, Lexington, KY. 1992 Travel Grant from the International Society of Nephrology to attend the XIth International, Congress of Nephrology, July 15-20,1990, Tokyo, Japan. IX. PROFESSIONAL ACTIVITY AND PUBLIC SERVICE Public Service 2001-present NIH Consultant, NCCAM Review Committee Member 2002 Ad Hoc External Consultant, Kidney Foundation of Canada Ad Hoc Reviewer American Journal of Kidney Disease American Journal of Hypertension American Journal of Medicine American Journal of Pathology American Journal of Physiology Bone Kidney International Life Sciences Nephrology, Dialysis and Transplantation Doody Publishing, Inc., 2000-present Journal of the American College of Nutrition, 2000 Professional Affiliations American Society of Nephrology International Society of Nephrology American Federation for Medical Research Central Society for Clinical Research ASH Specialist in Clinical Hypertension 2
  • 3. Paolo Fanti, M.D. X. SPEAKING ENGAGEMENTS Local: 2000 “Clinical applications of soy protein", Internal Medicine Grand Rounds, University of Kentucky 1999 “Genetic polymorphism of detoxifying enzymes and manifestations of chronic renal disease”, DCI dietitian CME Meeting, Lexington, KY 1999 “Advancement in the Diagnosis of Hyperaldosteronism”, Nephrology Grand Rounds, University of Kentucky“ 1999 “Cross-analysis of Cytochrome P450-2D6 and Gluathione S-transferase-M1 Gene Polymorphism in ESRD Patients”, Nephrology Research Conference, University of Kentucky 1999 “Plant Protein in the Management of Chronic Renal Failure”, Nephrology Grand Rounds, University of Kentucky 1998 “Evaluation and Management of Patients with Kidney Stones”, Internal Medicine Grand Rounds, University of Kentucky 1996 “Phytoestrogens, menopause and bone”, Nutritional Science Seminars, University of Kentucky. State: 2001 “Clinical applications of soy protein” Kentucky Dietetic Association, Annual meeting. Florence, KY. 2000 “Metabolism of isoflavones in humans” Dayton Cincinnati Renal Nutrition Fall Symposium, Cincinnati, OH 1999 “Soy protein and progression of chronic renal disease” Kentucky Dietetic Association, Lexington, KY 1999 “Soy protein and progression of renal failure” Kentucky Renal Dieticians Spring Meeting, Simpsonville, KY 1998 “Soyfoods and Chronic Renal Disease” Third Annual Soyfoods Symposium of the Kentucky Soybean Association, Louisville, KY 1998 “Soy and health - Beneficial effects of soy on bone and mineral balance” Kentucky Soybean Association, Fourth Annual Commodity Conference, Bowling Green, KY 1997 “An overview of hypertension: Pathophysiology and consequences”.UK CME Program. Appalachian Regional Hospital, Hazard, KY 1997 “Soy to your health - The case for beneficial effects of soy on bone and mineral balance” Kentucky Soybean Association, 8th Annual Leadership Conference, Dawson Springs, KY 1997 “Calcium Oxalate Stones: The General Practitioner and Internist Perspective”, University of Kentucky CME Program, Family Medicine Review, Lexington, KY 1996 “Calcium Oxalate Stones: The General Practitioner and Internist Perspective”, University of Kentucky CME Program, Marymount Hospital, London, KY. 1995 “Calcium Oxalate Stones: The General Practitioner and Internist Perspective”, University of Kentucky CME Program, Johnson Mathers Health Care Center, Carlisle, KY National: 2001 “Prevention and Early Management of Diabetic Renal Disease.” Souther Medical Association’s 4th Annual Conference on Diabetes, Destin, FL. 2001 “Dietary soy intervention: studies on progression of renal disease and on secondary manifestations of established chronic renal failure.” Nephrology Grand Rounds, Univ. of Southern California, Los Angeles, CA. 2001 "Dietary soy intervention: effects on progression of renal disease and on secondary manifestations of End-Stage Renal Failure." Nephrology Grand Rounds, University of Virginia, Charlottesville, VA. 2001 “Dietary soy intervention: effects on progression of renal disease and on secondary manifestations of End-Stage Renal Failure." Council Of Renal Nutrition of New England, Spring Meeting, New Britain, CT 2000 “Use of soy protein in preventing and treating chronic disease.” National Kidney Foundation Clinical Nephrology Meeting 2000, Atlanta, GA 2000 “Soy protein and progression of chronic renal disease.” ESRD Networks 9&10 – 2000 Nephrology Conference, Chicago, IL 2000 “Genetic polymorphism of detoxifying enzymes. Studies on the impact on progression of chronic renal disease and on the secondary manifestations of ESRD.” Nephrology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI. 2000 “Genetic polymorphism of detoxifying enzymes. Studies on the impact on progression of chronic renal disease and on the secondary manifestations of ESRD.” Nephrology Grand Rounds, University of Tennessee, Memphis, TN. 2000 “Metabolism of isoflavones in humans.” 8th Biennial Conference of the Cellular and Molecular Biology fo the Soybean, Lexington, KY 3
  • 4. Paolo Fanti, M.D. International: 1999 “Soy isoflavones and chronic renal disease” World Soybean Research Conference VI, Chicago, IL 1996 “Phytoestrogens and prevention of postmenopausal bone loss.” Institute of Pathology Seminars, Second University of Naples, Italy 1996 “Systemic administration of genistein partially prevents bone loss in ovariectomized rats via a non-estrogenic mechanism.” Second International Symposium on “The Role of Soy in Preventing and Treating Chronic Disease”. Brussels, Belgium 1994 “Effects of aluminum on osteocalcin expression in ROS 17/2 cells." Advances in Mineral Metabolism, Snowmass, Colorado XI. RESEARCH AND/OR SCHOLARSHIP Peer-reviewed Papers 1. Frasca, G., A. Vangelista, P. FANTI, V. Bonomini, G. Biagini, B. Severi. Evolution and morphological characteristics of mesangial proliferative glomerulonephritis with deposit of IgM. Minerva Nefrologica, 27:555- 558, 1980. 2. Malluche, H.H., M.C. Faugere, P. FANTI, P.A. Price. Plasma levels of bone Gla -protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 26:869 874, 1984. 3. Akmal, M., S.G. Massry, D.A. Goldstein, P. FANTI, A. Weisz, R.A. DeFronzo. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J. Clin. Invest. 75:1037-44, 1985. 4. Smith, A.J., M.C. Faugere, K. Abreo, P. FANTI, B. Julian, H.H. Malluche. Aluminum related bone disease in mild and advanced renal failure. Am. J. Nephrol. 6:275-283, 1986. 5. H.H. Malluche, C.M. Matthews, M.C. Faugere, P. FANTI, R.M. Friedler. 1,25 Dihydroxyvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology 119:1298-1304, 1986. 6. P. FANTI, A.J. Smith, P.A. Price, R.E. Reitz, H.H. Malluche. Effects of parathyroidectomy on circulating levels of 1,25-dihydroxyvitamin D and Bone GLA protein in dialyzed patients. J. Clin. Endocrinol. Metab. 62:869-873, 1986. 7. Malluche, H.H., M.C. Faugere, R.M. Friedler, C.M. Matthews, P. FANTI. Calcitriol, parathyroid hormone and the accumulation of aluminum in bone in dogs with renal failure. J. Clin. Invest. 79:754-761, 1987. 8. Malluche, H.H., M.C. Faugere, R.M. Friedler, P. FANTI. 1,25-Dihydroxyvitamin D3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs. Endocrinology 122:1998-2006, 1988. 9. Baker, L.R.I., S.M.L. Abrams, C.J. Roe, M-C Faugere, P. FANTI, Y. Subayti, H.H. Malluche. 1,25(OH)2D3 administration in moderate renal failure: A prospective double blind trial. Kidney Int. 35:661-669, 1989. 10. Dunlay, R.W., M. Camp, M. Allon, H.H. Malluche, P. FANTI, F. Llach. The role of calcitriol in prolonged hypocalcemia due to tumor lysis syndrome. Ann. Internal Med. 110:162-164, 1989. 11. Faugere, M.C., R.M. Friedler, P. FANTI, H.H. Malluche. Bone changes occurring early after cessation of ovarian function in Beagle dogs; a histomorphometric study employing sequential biopsies. J. Bone Min. Res. 5:263-272, 1990. 12. Letton, R.W., P. FANTI, H.H. Malluche. Regulation of 25(OH)D metabolism in cultures of osteoblastic cells. J. Bone Min. Res. 5:815-823, 1990. 4
  • 5. Paolo Fanti, M.D. Peer-reviewed Papers, cont’d 13. P. FANTI, M.S. Kindy, S. Mohapatra, J. Klein, G. Colombo, H.H. Malluche. Dose dependent effect of aluminum on osteocalcin synthesis in osteoblast-like ROS 17/2 cells in culture. Am. J. Physiol. 263:E1113-1118, 1992. 14. Ott, M.T., P. FANTI, H.H. Malluche, U.Y. Ryo, F.S. Whaley, W.E. Strodel, T.C. Colacchio. Biochemical evidence of metabolic bone disease in women following the roux-y gastric bypass procedure for morbid obesity. Obesity Surgery 2:341-348, 1992. 15. Rush, J.S., J. Klein, P. FANTI, N.R. Bhat, C.J. Waechter. Direct assay of membrane associated protein kinase C activity in B lymphocytes in the presence of Brij 58. Analyt. Biochem. 207:304-310, 1992. 16. Colombo, G., P. FANTI, C. Yao, H.H. Malluche. Isolation and complete amino acid sequence of osteocalcin from canine bone. J. Bone Min. Res. 8:733-743, 1993. 17. P. FANTI, G. Colombo, C. Yao, S. Brown, M.W. Vernon, H.H. Malluche. Development and characterization of a polyclonal antiserum-based radioimmunoassay for dog osteocalcin. J. Bone Min. Res. 8:745-752, 1993. 18. Carter, S.D., G.L. Cromwell, T.R. Combs, G. Colombo, P. FANTI. The determination of serum concentration of osteocalcin in growing pigs and its relationship to end measures of bone mineralization. J. Anim. Sci. 74:2719- 2729, 1996. 19. P. FANTI, M.C. Monier-Faugere, Z. Geng, J. Schmidt, D. Cohen, H.H. Malluche. Moderately high consumption of ethanol suppresses bone resorption in ovariectomized but not in sexually intact adult female rats. Alcohol. Clin. Exper. Res. 21:1150-1154, 1997. 20. P. FANTI, M.-C. Faugere, Z. Gang, J. Schmidt, P.E. Morris, D. Cohen, H.H. Malluche. The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporosis Int. 8:273-280, 1998. 21. P. FANTI, B.P. Sawaya, L.J. Custer, A.A. Franke. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J. Am. Soc. Nephrol. 10:846-871, 1999. 22. Carter, S.D., G.L. Cromwell, G. Colombo, P. FANTI. Effects of porcine somatotropin on calcium and phosphorus balance and markers of bone metabolism in finishing pigs. J. Anim. Sci., 77:2163-2171, 1999. 23. Morris P., L.E. Olmstead, A.E. Howard-Carrol, G.R. Dickens, M.L. Goltz, C. Courtney-Shapiro, P. FANTI. In vitro and in vivo effects of genistein on murine alveolar macrophage TNFα production. Inflammation, 23:231- 239, 1999. 24. Sawaya, B.P., M.C. Faugere, P. Ratanapanichkich, R Butros, P.J. Wedlund, P. FANTI, . Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism. Clinical Nephrology, 57:51-55, 2002. 25. F-X. Yan, M.A. Ihnen, M.C. Langub, C. Hornung, E. Juronen, M.-K. Rayens, P.J. Wedlund, P. FANTI. Expression of phase I and phase II detoxifying enzymes in human parathyroid tissue and impact of their genetic variation on circulating parathyroid hormone in ESRD patients. Submitted to , . 26. FANTI, P., T.J. Stephenson, I.M. Kaarianinen, B. Rezkalla, Y. Tsukamoto, T. Morishita, M. Nomura, C. Kitiyakara, L.J Custer, A.A. Franke. Soyfood Intake and Blood Isoflavones in Japanese, Thai and American ESRD Patients. Submitted to Kidney International, January 2002. 27. Sawaya, BP, Butros, R, Naqvi S, Geng Z, Mawad H, Friedler R, Fanti P, Monier-Faugere, MC, MALLUCHE HH: Differences in bone turnover and intact PTH levels between African-American and Caucasian patients with end-stage renal disease. Kidney Int, in press In Preparation 1. P. FANTI, B.P. Sawaya, T.J. Stephenson. Effects of Soy Isoflavones on the Immuno-Inflammatory Response of End-Stage Renal Disease (ESRD) patients on Chronic Hemodialytic Therapy (HD). 2. T.J. Stephenson, J.W. Anderson, P. FANTI. Beneficial Effects of Soy Protein Use on Renal Function in Young Type I Diabetics With Early Diabetic Nephropathy. 3. T.J. Stephenson, B.P. Sawaya, P. FANTI. Dietary Intake of a Soy Protein Isolate Supplement Improves Nutritional Status in Malnourished Hemodialysis Patients. 4. F-X. Yan, M. Ihnen, C. Hornung, P.J. Wedlund, P. FANTI. Genetic Polymorphisms of Glutathione S-Transferase M1 (GSTM1) and T1 (GSTT1) and parathyroid hormone levels in patients with renal failure; Racial differences between African Americans and Caucasians. 5
  • 6. Paolo Fanti, M.D. Non-Peer Reviewed Papers 1. Feletti, C., A. Buscaroli, A. DeFelice, P. FANTI, V. Bonomini. Is 1,25 dihydroxycholecalciferol (1,25 DHCC) effective in treatment of uremic osteodystrophy? In: Vitamin D. Chemical, Biochemical, and Clinical Endocrinology of Calcium Metabolism. Eds., A.W. Norman, K. Shaefer, D.V. Herrat, H.G. Grigoleit. Walter deGruyter, pp. 857-859, 1982. 5. Malluche, H.H., C.M. Matthews, M.C. Faugere, P. FANTI, R.M. Friedler. Parathyroid hormone in 1.25 Vitamin D3 exert opposite effects on bone. In: Phosphate and Mineral Homeostasis. Eds., S.G. Massry, M. Olmer and E. Ritz. Plenum Publishing Corp., pp. 289-290, 1986. 6. Baker, L.R.I., S.M.L. Abrams, C.J. Roe, M-C Faugere, P. FANTI, Y. Subayti, H.H. Malluche. Early therapy of renal bone disease with calcitriol: a prospective double -blind study. Kidney Int. 36(Suppl. 27):S140-S142, 1989. 7. Baker, L.R.I., C. Rose, S.M.L. Abrams, C.J. Roe, M-C Faugere, P. FANTI, Y. Subayti, H.H. Malluche. Administration of 1,25(OH)2D3 in patients with mild to moderate renal impairment corrects hyperparathyroid- related bone disease, but reduces bone turnover in bone morphometry. Proceedings of the Fifth International Congress on Bone Morphometry, edited by H. Takahashi, Smith-Gordon, Nishimura, 1990, pp. 290-294. 5. Franke, A.A., M.C. Yu, G. Maskarinec, P. FANTI, W. Zheng, L.J. Custer. Phytoestrogens in human biomatrices including breast milk. Biochemical Society Tansactions , 27:308-318, 1999. 6. Franke, A.A., M.C. Yu, P. FANTI, W. Zheng, Y. Tanaka, G. Maskarinec, R.V. Cooney, L.J. Custer. Cancer protection by dietary flavonoid agents. Proceedings of the Korean Association of Cancer Prevention, pp. 8-10, 1999. Books and Book Chapters 1. P. FANTI, P. Sawaya. Renal osteodystrophy and aluminum intoxication. In: Current Therapy in Nephrology and Hypertension. Ed, R.J. Glassock. Mosby-Year Book, Inc., pp.295-301, 1998. 2. P. FANTI. Clinical manifestations of chronic renal insufficiency. In: Clinical Nephrology, Dialysis and Transplantation. Eds., H.H. Malluche, B.P. Sawaya, R.M. Hakim, M.H Sayegh. Dustri-Verlag, Deisenhofen/Munich, Chapter I-18, pp.1-16, 1999. Abstracts (last 5 years) 1. FANTI, P., M.C. Faugere, Z. Gang, J. Schmidt, D. Cohen, H.H. Malluche. Genistein reduces bone loss in ovariectomized rats. J. Bone Min. Res. 12(Suppl. 1):S477, 1997. 2. FANTI, P., B.P. Sawaya, L.J. Custer, A.A. Franke. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J. Am. Soc. Nephrol. 8:283A, 1997. 3. Geng, Z.P., P Fanti, MC Faugere, D Cohen, HH Malluche. Moderately high consumption of ethanol suppresses histologic parameters of bone resorption in ovariectomized but not in sexually intact adult female rats. 82nd Fragrance Mountain Science Conference. 1997. Beijing, P.R. China. 4. FANTI, P., M.C. Faugere, Z. Gang, J. Schmidt, D. Cohen, H.H. Malluche. Systemic administration of genistein partially prevents bone loss in ovariectomized rats via a nonestrogen-like mechanism. Am. J. Clin. Nutr. 68(suppl):1517S, 1998. 5. FANTI, P., FX Yan, PJ Wedlund. Deficiency in cytochrome P450-2D6 (CYP2D6) is associated with extreme levels of parathyroid hormone in renal failure patients. J. Am. Soc. Nephrol., 9:564A, 1998. 6. Franke, A.A., L.J. Custer, P. FANTI, W.Zheng. Phytoestrogens in human milk and other biomatrices. Biochemistry Society Meeting, September 21-23, 1998, London/UK. 7. Hanna, T.J., P. FANTI, JW Anderson. Soy protein decreases workload of kidneys in type I diabetics at risk for diabetic nephropathy. FASEB J. 13(Suppl. S):A272, 1999. 8. Fanti P., P. Ratanapanichkich, A. Buscaroli, F.X. Yan, P.J. Wedlund. Non-functional genes for Cytochrome P450-2D6 and Glutathione S-transferase-M1 are associated with very low and very high levels of parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transpl 14:A38, 1999. 9. Hanna, T.J., P. FANTI, JW Anderson. Beneficial effects of soy protein in type I diabetic patients at risk for nephropathy; a preliminary report. Third International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. October 31-November 3, 1999, Washington, DC. 10. FANTI, P., P. Ratanapanichkich, F.X. Yan, P.J. Wedlund. Concomitant deficiency in cytochrome P450-2D6 6
  • 7. Paolo Fanti, M.D. (CYP2D6) and glutathione s-transferase-m1 (GSTM1) genes is associated with inappropriately normal or very high levels of parathyroid hormone (PTH) in ESRD patients. J. Am. Soc. Nephrol., 10:618A, 1999. 11. FANTI, P., B. P. Sawaya, P. Ratanapanichkich, HH Malluche. African-Americans with ESRD have higher parathyroid hormone (PTH) levels at the initiation of renal replacement therapy (RRT). J. Am. Soc. Nephrol., 10:618A, 1999. 12. Ihnen, M., F.X. Yan, P.J. Wedlund., P. FANTI. Combined deficiency in glutathione S-transferase -M1 (GST-M1) and T1 (GST-T1) genes is associated with high levels of parathyroid hormone (PTH) in ESRD patients. Am. J. Kidney Dis., 35:14A, 2000. 13. Ihnen, M., F.X. Yan, P.J. Wedlund., P. FANTI. The combination of non-functional Glutathione-S-Transferase- M1 (GST-M1) and T1 (GST-T1) genes is associated with very high parathyroid hormone (PTH) in ESRD patients. J. Am. Soc. Nephrol., 11:577A, 2000. 14. Sawaya, P.B., R. Butros, M.C. Monier-Faugere, Z. Geng, P. FANTI, H.H. Malluche. Bone turnover in patients with ESRD and moderately elevated serum parathyroid hormone (PTH): Evidence for the usefulness of evaluating the trend in PTH levels. J. Am. Soc. Nephrol., 11:582A, 2000. 15. Stephenson, T.J., J.W. Anderson, P. FANTI. Soy Protein Use In Early Diabetic Nephropathy. Alternative Therapies, 7:S31, 2001. 16. FANTI, P, Y. Tsukamoto, C. Kitiyakara, A.A. Franke, I.M. Kaarianinen, T.J. Stephenson. Soyfoods Intake And Blood Levels Of Soy Isoflavones In Japanese, Thai And North American End-Stage Renal Failure Patients On Chronic Hemodialysis Therapy. Alternative Therapies, 7:S11, 2001. 17. T.J. Stephenson, J.W. Anderson and P. FANTI. Dietary Intake of Soy Ameliorates Glomerular Hyperfiltration and Lowers Cholesterol in Type 1 Diabetic Patients. J. Am. Soc. Nephrol., 12:157A, 2001. 18. FANTI, P, Y. Tsukamoto, C. Kitiyakara, A.A. Franke, I.M. Kaariainen and T.J. Stephenson. Soyfoods Intake and Blood Levels of Soy Isoflavones in Japanese, Thai and North American End-Stage Renal Disease (ESRD) Patients (Pts) on Chronic Hemodialysis (HD). J. Am. Soc. Nephrol., 12:355A, 2001. 19. Langub, M.C., E. Juronen, P.J. Wedlund and P. FANTI. Immunohistochemical Localization of the Detoxifying Enzymes CYP2D6, GST-M1 and GST-T1 in Human and Porcine Parathyroid Tissue (PT). J. Am. Soc. Nephrol., 12:767A, 2001. 20. Sawaya, B.P., M.C. Monier-Faugere, R Butros, Z Geng, H Mawad, R. Friedler, P. FANTI, H. Malluche. Intact Parathyroid Hormone Levels are not Predictive of Bone Turnover in African American Patients with ESRD. J. Am. Soc. Nephrol., 12:772A, 2001. 21. P. FANTI, Y. Tsukamoto, C. Kitiyakara, A.A. Franke, I.M. Kaariainen, T.J. Stephenson. Comparison of Dietary Soyfoods Consumption and Blood Levels of Soy Isoflavones in Japanese, Thai and North American End-Stage Renal Disease (ESRD) Patients (Pts) on Chronic Hemodialysis (HD). 4th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, San Diego, CA, 2001. 22. P. FANTI, B.P. Sawaya, T.J. Stephenson. Effects of Soy Isoflavones on the Immuno-Inflammatory Response of End-Stage Renal Disease (ESRD) patients on Chronic Hemodialytic Therapy (HD). 4th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, San Diego, CA, 2001. 23. T.J. Stephenson, B.P. Sawaya, P. FANTI. Dietary Intake of a Soy Protein Isolate Supplement Improves Nutritional Status in Malnourished Hemodialysis Patients. 4th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, San Diego, CA, 2001. 24. T.J. Stephenson, J.W. Anderson, P. FANTI. Beneficial Effects of Soy Protein Use on Renal Function in Young Type I Diabetics With Early Diabetic Nephropathy. 4th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, San Diego, CA, 2001 25. W. Cai, R. Pan, M. Ihnen, M.C. Langub, P. FANTI, P.J. Wedlund. Polymorphisms in Drug Metabolism Enzymes in Patients with End Stage Renal Disease. Meeting of the American Association of Pharmaceutical Scientists, Denver, CO, 2001. Grants Grants Received NIH-RO1AM32467 - Effects of vitamin D metabolites and PTH on bone 9/1/82-8/1/85 - $129,508; co-investigator. 7
  • 8. Paolo Fanti, M.D. NIH-RO1AM34419 - Aluminum in bone and muscle abnormalities in uremia 9/1/84-8/1/88 - $333,314; co-investigator. DCI Institutional Training Grant, Project #209; 7/l/85-6/87. NIH-RO1AR35837 - Bone loss after ovariectomy 4186-3189 - $225,743; 4/91-3/1/95 - $378,663; co-investigator. VA Research Advisory Group - Effects of aluminum on bone cells in culture 7/1/91-6/1/93 - $64,560; principal investigator. University of Kentucky General Clinical Research Center - Effect of the acute administration of calcitonin on 25(OH)2 vitamin D metabolism in normal volunteers. Pilot study. 3/1/92-3/1/93 - $1,550; principal investigator. University of Kentucky Medical Center Research Grant # 93-658 - Effect of aluminum on the parathyroid hormone- stimulated synthesis of osteocalcin in cultures of osteoblast-like cells. 7/1/93-6/1/94 - $14,988; principal investigator. University of Kentucky Department of Internal Medicine Professional Development Fund - Effects of Insulin and the Insulin-Like Growth Factors on Osteocalcin Gene Expression - Summer 1994-Summer 1995 - $24,065; principal investigator. Dialysis Clinic Incorporated Research Fund - Effects of aluminum and PTH on osteocalcin synthesis in osteoblastic cells in culture. Summer 94-Summer 96 - $40,000; principal investigator. Hoffman-La Roche Ltd. - A comparison of the safety and the efficacy of mibefradil and amlodipine in patients on urinary albumin excretion, glucose and lipid metabolism and renal function in hypertensive non-diabetic and non- insulin dependent diabetic patients. 9/97 - 3/98. $28,560. Principal Investigator (15% effort) Merck & Co., Inc. - A double blind, randomized, parallel effectiveness study of two hyprtensive treatment regimens; losartan versus valsartan in patients with mild to moderate essential hypertension. $18,000. Principal Investigator (10% effort) University of Kentucky General Clinical Research Center Grant - Soybean and Urine Lithogenicity in Patients with Recurrent Calcium Oxalate Nephrolithiasis. - 9/1/96-8/31/98 - $45,926; Principal Investigator. UKMC Research Fund - Renal disease and the CYP2D6 enzyme polymorphism in the kidney. $15,000. Co- investigator. Merck & Co., Inc. -Losartan intervention for endpoint reduction in hypertension. $18,000. Principal Investigator ($6,000) Kentucky Soybean Promotion Board - Beneficial effects of soy protein on urine composition and bone metabolism in patients with recurrent formation of calcium-containing kidney stones. 7/1/97 - 6/30/00. $30,000. Principal Investigator. Kentucky Soybean Promotion Board - Beneficial effects of the soy constituent genistein on postmenopausal bone. 7/1/97 - 6/30/00. $30,000. Principal Investigator. Protein Technologies International - Anti-oxidant and anti-inflammatory effects of dietary isoflavones in ESRD - 9/1/99 to 8/31/00. $25,391. Principal Investigator. Amgen Inc. – NESP 990788. “A study evaluating the initiation of fixed doses of novel erythropoiesis stimulating protein (NESP) therapy in subjects with chronic renal insufficiency.” 2/1/01 to 8/1/01. Principal Investigator. $11,980. Active Grants NIH – AT00323-01 - Soy protein use in early diabetic nephropathy. 2/1/00 to 1/31/02. Principal Investigator (15% effort). $198,232 (direct). NIH – AT00205-01 - Isoflavones and acute-phase response in chronic renal failure. 7/15/01 to 6/30/03. Principal Investigator (30% effort). $200,000 (direct). Kidney Foundation of Central Kentucky – Soyfoods and prevention of renal disease in an animal model of Type I Diabetes Mellitus. Role of renal hemodynamics and renal microvascular production of nitric oxide. 6/1/00 – 12/31/02. Principal Investigator (no effort). $18,897 (direct). Novartis Pharmaceuticals Corp. – A randomized, double-blind, placebo-controlled, multi-center study on the efficacy and safety of long-term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT). 10/23/01 – 10/1/06. Principal Investigator (5% effort). $120,000. 8
  • 9. Paolo Fanti, M.D. Pending Grants NutriPharma - Multicenter, randomised, double -blind, parallel group, 6 months study comparing the effects of Abalon® with placebo on hyperlipidemia, hyperglycemia and kidney function in Type 2 Diabetes patients. 9/1/01 to 12/30/02. Co-Investigator (10% effort) $220,000. Update 4/15/03 9